AI Article Synopsis
- * After 57 months of treatment, she experienced an atypical femoral fracture in her right femur, requiring surgery.
- * Twenty months later, she fractured her left femur and needed further surgical intervention, highlighting the risk of atypical fractures associated with bone treatments like zoledronic acid in breast cancer patients.
Article Abstract
A 54-year-old woman developed stage IV breast cancer 8 years prior. Chemotherapy was administered, and she was started on zoledronic acid treatment for her bone metastases. Her chemotherapy regimen was then switched, owing to disease progression. Fifty-seven months after starting treatment with zoledronic acid, the patient suffered an atypical femoral fracture of her right femur, for which she underwent surgery. Twenty months later, she developed another atypical femoral fracture in her left femur and underwent intramedullary nail fixation. Zoledronic acid and denosumab use in patients with metastatic bone tumors caused by breast cancer should be done cautiously, considering atypical femoral fracture risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/mrcr/rxae059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!